Syneos Health, Inc. - (SYNH) News
Filter SYNH News Items
SYNH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SYNH News Highlights
- For SYNH, its 30 day story count is now at 9.
- Over the past 20 days, the trend for SYNH's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about SYNH are DRUG, ML and SNCE.
Latest SYNH News From Around the Web
Below are the latest news stories about SYNEOS HEALTH INC that investors may wish to consider to help them evaluate SYNH as an investment opportunity.
Syneos Health Launches Medical Affairs Digital AmplifierProgram Drives Digital and Omnichannel Engagement for Medical Science Liaison Teams & Medical ConferencesMORRISVILLE, N.C., March 27, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical Affairs Digital Amplifier, a program designed to drive smarter and more effective scientific exchange. This integrated program seeks to ensure customers, and the clinicians they serve, have access to the |
Syneos Health (SYNH) Partners With KX for Data-Driven InsightsSyneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions. |
Syneos Health and KX Partner to Pioneer Data-Driven Transformation in Biopharmaceutical Asset DevelopmentCollaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial ExecutionMORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with KX, maker of kdb, the world’s fastest time series database and analytics engine. The partnership will deliver data-driven predictive analytics, Artificial Intelligence (AI) and Machine Learning (ML) capabilities to |
Syneos Health's (SYNH) New Microsoft Deal to Expand AI UsageWith the multi-year deal, Syneos Health (SYNH) aims to deliver technology and data solutions with Microsoft. |
Syneos Health Collaborates with Microsoft to Accelerate AI Across the Clinical to Commercial ContinuumCollaboration Leverages AI-ready Technology to Speed Asset Development and Optimize PerformanceMORRISVILLE, N.C., March 20, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic multi-year agreement with Microsoft. Utilizing Microsoft Azure services, Syneos Health has developed an advanced analytics platform that enables agile deployment of machine learning (ML) supporting the analysis, design and e |
Should You Exit Your Position in Syneos Health (SYNH)?Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund returned 4.69% (net) compared to a 4.72% return for the Russell 2500 Growth Index. Positive factors during the quarter helped the fund’s performance. An emphasis […] |
Syneos Health's (SYNH) Product Launch Aids, FX Woe HurtsSyneos Health (SYNH) remains confident about the long-term strength of its business, given its robust backlog and unique market position. |
Should You Be Adding Syneos Health (NASDAQ:SYNH) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to... |
Science 37 expects revenue slump as drug industry strugglesAs challenges in the drug development industry persist, Science 37 (Nasdaq: SNCE) is anticipating a drop in revenue this year. After finishing last year at $70.1 million, the clinical research company based in Research Triangle Park is projecting revenue in 2023 to total between $55 million to $60 million. CEO David Coman said this guidance is partly based on industrywide issues, which include drug funding challenges, pharma and biotech companies taking longer to make decisions and drug developers being more cost conscious. |
Syneos Health Unveils New Decentralized Clinical Trial Site Network to Drive DCT AdoptionNewly Established Network Will Enable High Quality DCTs & Digital Health Technology SolutionsMORRISVILLE, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of a Decentralized Clinical Trial (DCT) Site Network to drive appropriate DCT adoption and enable high quality delivery of DCTs and digital health technology solutions. The introduction of the Syneos Health DCT Site Network com |